MedTrace Logo

A Study on Health - Related Quality of Life in Patients With Rheumatic Diseases Taking Tramadol 37.5mg/Acetaminophen 325mg Tablets

NCT00642837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 982

Last updated 2014-04-28

No results posted yet for this study

Summary

The objective of this observational study is to assess improvement of quality of life in the patients who are administered Tramadol 37.5mg/Acetaminophen 325mg tablets for 10\~14 weeks according to the investigator's discretion in clinical practice.

Conditions

  • Rheumatic Diseases

Interventions

DRUG

Tramadol/acetaminophen

Osteoarthritis, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Post surgical neurophatic pain, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Post traumatic neuropathic pain, flexible dose depending on patient pain relief

DRUG

Tramadol/acetaminophen

Spinal Cord Injury, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Diabetic Neuropathy, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Post stroke pain, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Low back pain, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Post Herpetic Neuralgia, flexible dose depending on patients' pain relief

DRUG

Tramadol/acetaminophen

Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    lead INDUSTRY

Principal Investigators

  • Janssen Korea, Ltd. Clinical Trial · Janssen Korea, Ltd.

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2008-05-31
Completion
2008-05-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00642837 on ClinicalTrials.gov